Table 4.
Rectal SEER Analysis: 5-Year Relative and Observed Survival by TN Category of Disease in Patients With Invasive Cancer and Evaluable TN Category
| TN Category | No. Patients | SEER: 5-Year Relative Survival Rate (%) | SE (%) | TNM Stage (sixth edition) | Proposed TNM Stage (seventh edition) | SEER: Observed Survival Rate (%) | SE (%) |
|---|---|---|---|---|---|---|---|
| T1N0 | 3,348 | 96.6 | 0.9 | I | I | 81.4 | 0.8 |
| T2N0 | 6,613 | 92.1 | 0.7 | I | I | 75.7 | 0.6 |
| T3N0 | 10,615 | 78.7 | 0.7 | IIA | IIA | 64.0 | 0.5 |
| T4aN0 | 818 | 69.2 | 2.4 | IIB | IIB | 55.7 | 1.9 |
| T4bN0 | 769 | 53.6 | 2.5 | IIB | IIC* | 44.7 | 2.1 |
| T1-2N1 | 2,008 | 85.1 | 1.4 | IIIA | IIIA | 72.1 | 1.2 |
| T1N2a | 62 | 82.7 | 7.0 | IIIC | IIIA* | 73.8 | 6.2 |
| T2N2a† | 302 | 67.7 | 4.0 | IIIC | IIIB* | 58.2 | 3.4 |
| T3N1a | 2,758 | 66.9 | 1.4 | IIIB | IIIB | 55.4 | 1.1 |
| T4aN1a | 218 | 65.6 | 4.6 | IIIB | IIIB | 53.2 | 3.7 |
| T3N1b | 3,029 | 59.7 | 1.3 | IIIB | IIIB | 49.7 | 1.1 |
| T1N2b | 24 | 59.3 | 14.6 | IIIC | IIIB* | 53.2 | 13.0 |
| T4aN2a‡ | 199 | 53.1 | 4.8 | IIIC | IIIC | 44.3 | 4.0 |
| T4aN1b | 262 | 52.6 | 4.1 | IIIB | IIIB | 43.9 | 3.4 |
| T3N2a | 1,964 | 49.9 | 1.5 | IIIC | IIIB* | 42.5 | 1.3 |
| T2N2b | 120 | 46.2 | 5.8 | IIIC | IIIB* | 41.7 | 5.0 |
| T3N2b | 1,791 | 37.5 | 1.5 | IIIC | IIIC | 32.0 | 1.3 |
| T4aN2b | 198 | 28.5 | 4.0 | IIIC | IIIC | 24.5 | 3.4 |
| T4bN1 | 423 | 28.5 | 2.9 | IIIB | IIIC* | 24.3 | 2.5 |
| T4bN2a | 156 | 22.1 | 4.3 | IIIB | IIIC | 18.5 | 3.6 |
| T4bN2b | 152 | 14.1 | 4.0 | IIIC | IIIC | 12.3 | 3.5 |
NOTE. Survival outcomes of 35,829 patients with invasive T1-4N0-2 rectal cancer are shown.
Abbreviation: SEER, Surveillance, Epidemiology, and End Results.
*
Changes in substaging of stages II and III are based on expanded outcomes in SEER rectal/colon analyses.
†
T2N2a rectal lesions did worse than colon T2N2a lesions; both categories are placed in stage IIIB.
‡
T4aN2a rectal lesions did better than colon T4aN2a lesions; both categories are placed in stage IIIC.